Get started
HUBEI JUMPCAN PHARMACEUTICAL COHH

HUBEI JUMPCAN PHARMACEUTICAL CO

27.80CNYD
−0.22−0.79%
At close at Mar 28, 08:49 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

600566 fundamentals

Key facts

Market capitalization‪25.62 B‬CNY
Dividend yield (indicated)4.68%
Price to earnings Ratio (TTM)7.79
Basic EPS (TTM)3.60CNY
Founded1997
Employees (FY)‪5.23 K‬
CEOFei Cao
Websitejumpcan.com
About

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs & pharmaceutical products. Its product covers the pediatrics, breathing, and digestion field. The company was founded on January 22, 1997 and is headquartered in Taizhou, China.

Ownership
‪‪916.22 M‬‬
Closely held shares
‪‪586.18 M‬‬ (63.98%)
Free Float shares
‪‪330.04 M‬‬ (36.02%)
Closely held shares
‪‪586.18 M‬‬ (63.98%)
Free Float shares
‪‪330.04 M‬‬ (36.02%)
Capital structure
Market cap
‪‪25.62 B‬‬
Debt
‪‪1.61 B‬‬
Minority interest
‪‪23.94 M‬‬
Cash & equivalents
‪‪11.70 B‬‬
Enterprise value
‪‪15.55 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪25.62 B‬‬
Price to earning ratio (P/E)
7.79x
Price to sales ratio (P/S)
2.92x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
7.79x
Price to sales ratio (P/S)
2.92x
Valuation ratios
‪0.00‬
‪1.00‬
‪2.00‬
‪3.00‬
‪4.00‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪25%‬
‪28%‬
‪31%‬
‪34%‬
‪37%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Traditional Chinese Medicine
Western Medicine
Other
Other Business
By country
Period: 2023
China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪800.00 M‬‬
‪‪1.60 B‬‬
‪‪2.40 B‬‬
‪‪3.20 B‬‬
Actual
Earnings
Next:Apr 26, 2025
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪0.25‬
‪0.50‬
‪0.75‬
‪1.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
36.12%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
4.68%
Last payment
1.30
Last ex-date
Jun 17, 2024
Dividend history
‪2.0%‬
‪2.8%‬
‪3.6%‬
‪4.4%‬
‪5.2%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.35‬
‪0.70‬
‪1.05‬
‪1.40‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
‪‪12.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Assets
Liabilities